87 related articles for article (PubMed ID: 33995277)
21. KCNJ5 mutations in aldosterone- and cortisol-co-secreting adrenal adenomas.
Yamada M; Nakajima Y; Taguchi R; Okamura T; Ishii S; Tomaru T; Ozawa A; Shibusawa N; Yoshino S; Toki A; Ishida E; Hashimoto K; Satoh T; Mori M
Endocr J; 2012; 59(8):735-41. PubMed ID: 22863749
[TBL] [Abstract][Full Text] [Related]
22.
Chang YY; Tsai CH; Peng SY; Chen ZW; Chang CC; Lee BC; Liao CW; Pan CT; Chen YL; Lin LC; Chang YR; Peng KY; Chou CH; Wu VC; Hung CS; Lin YH;
Hypertension; 2021 Jan; 77(1):114-125. PubMed ID: 33249859
[TBL] [Abstract][Full Text] [Related]
23. Taiwan mini-frontier of primary aldosteronism: Updating detection and diagnosis.
Chang CC; Chen YY; Lai TS; Zeng YH; Chen CK; Tu KH; Lu CC; Wu VC; Er LK;
J Formos Med Assoc; 2021 Jan; 120(1 Pt 1):121-129. PubMed ID: 32855034
[TBL] [Abstract][Full Text] [Related]
24. THERAPY OF ENDOCRINE DISEASE: Medical treatment of primary aldosteronism.
Lechner B; Lechner K; Heinrich D; Adolf C; Holler F; Schneider H; Beuschlein F; Reincke M
Eur J Endocrinol; 2019 Oct; 181(4):R147-R153. PubMed ID: 31299637
[TBL] [Abstract][Full Text] [Related]
25. KCNJ5 Somatic Mutation Is a Predictor of Hypertension Remission After Adrenalectomy for Unilateral Primary Aldosteronism.
Vilela LAP; Rassi-Cruz M; Guimaraes AG; Moises CCS; Freitas TC; Alencar NP; Petenuci J; Goldbaum TS; Maciel AAW; Pereira MAA; Silva GV; Pio-Abreu A; Zerbini MCN; Cavalcante ACBS; Carnevale FC; Pilan B; Yamauchi F; Srougi V; Tanno FY; Chambo JL; Latronico AC; Mendonca BB; Fragoso MCBV; Bortolotto LA; Drager LF; Almeida MQ
J Clin Endocrinol Metab; 2019 Oct; 104(10):4695-4702. PubMed ID: 31216002
[TBL] [Abstract][Full Text] [Related]
26. MANAGEMENT OF ENDOCRINE DISEASE: Diagnosis and management of primary aldosteronism: the Endocrine Society guideline 2016 revisited.
Williams TA; Reincke M
Eur J Endocrinol; 2018 Jul; 179(1):R19-R29. PubMed ID: 29674485
[TBL] [Abstract][Full Text] [Related]
27. Targeted treatment of primary aldosteronism - The consensus of Taiwan Society of Aldosteronism.
Huang KH; Yu CC; Hu YH; Chang CC; Chan CK; Liao SC; Tsai YC; Jeff Chueh SC; Wu VC; Lin YH;
J Formos Med Assoc; 2019 Jan; 118(1 Pt 1):72-82. PubMed ID: 29506889
[TBL] [Abstract][Full Text] [Related]
28. GENETICS IN ENDOCRINOLOGY: The expanding genetic horizon of primary aldosteronism.
Monticone S; Buffolo F; Tetti M; Veglio F; Pasini B; Mulatero P
Eur J Endocrinol; 2018 Mar; 178(3):R101-R111. PubMed ID: 29348113
[TBL] [Abstract][Full Text] [Related]
29. Value of
Lv Z; Fan J; Xu J; Wu F; Huang Q; Guo M; Liao T; Liu S; Lan X; Liao S; Geng W; Jin Y
Eur J Nucl Med Mol Imaging; 2018 May; 45(5):735-750. PubMed ID: 29164298
[TBL] [Abstract][Full Text] [Related]
30. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis.
Monticone S; D'Ascenzo F; Moretti C; Williams TA; Veglio F; Gaita F; Mulatero P
Lancet Diabetes Endocrinol; 2018 Jan; 6(1):41-50. PubMed ID: 29129575
[TBL] [Abstract][Full Text] [Related]
31. KCNJ5 mutation as a predictor for resolution of hypertension after surgical treatment of aldosterone-producing adenoma.
Kitamoto T; Omura M; Suematsu S; Saito J; Nishikawa T
J Hypertens; 2018 Mar; 36(3):619-627. PubMed ID: 29016532
[TBL] [Abstract][Full Text] [Related]
32. Macrolides Blunt Aldosterone Biosynthesis: A Proof-of-Concept Study in
Caroccia B; Prisco S; Seccia TM; Piazza M; Maiolino G; Rossi GP
Hypertension; 2017 Dec; 70(6):1238-1242. PubMed ID: 28993452
[TBL] [Abstract][Full Text] [Related]
33. Macrolides selectively inhibit mutant KCNJ5 potassium channels that cause aldosterone-producing adenoma.
Scholl UI; Abriola L; Zhang C; Reimer EN; Plummer M; Kazmierczak BI; Zhang J; Hoyer D; Merkel JS; Wang W; Lifton RP
J Clin Invest; 2017 Jun; 127(7):2739-2750. PubMed ID: 28604387
[TBL] [Abstract][Full Text] [Related]
34. Primary aldosteronism as a public health issue.
Funder JW
Lancet Diabetes Endocrinol; 2016 Dec; 4(12):972-973. PubMed ID: 27886747
[No Abstract] [Full Text] [Related]
35. Associations Between Somatic Mutations and Metabolic Imaging Phenotypes in Non-Small Cell Lung Cancer.
Yip SS; Kim J; Coroller TP; Parmar C; Velazquez ER; Huynh E; Mak RH; Aerts HJ
J Nucl Med; 2017 Apr; 58(4):569-576. PubMed ID: 27688480
[TBL] [Abstract][Full Text] [Related]
36. Adrenal vein sampling versus CT scan to determine treatment in primary aldosteronism: an outcome-based randomised diagnostic trial.
Dekkers T; Prejbisz A; Kool LJS; Groenewoud HJMM; Velema M; Spiering W; Kołodziejczyk-Kruk S; Arntz M; Kądziela J; Langenhuijsen JF; Kerstens MN; van den Meiracker AH; van den Born BJ; Sweep FCGJ; Hermus ARMM; Januszewicz A; Ligthart-Naber AF; Makai P; van der Wilt GJ; Lenders JWM; Deinum J;
Lancet Diabetes Endocrinol; 2016 Sep; 4(9):739-746. PubMed ID: 27325147
[TBL] [Abstract][Full Text] [Related]
37. Study Heterogeneity and Estimation of Prevalence of Primary Aldosteronism: A Systematic Review and Meta-Regression Analysis.
Käyser SC; Dekkers T; Groenewoud HJ; van der Wilt GJ; Carel Bakx J; van der Wel MC; Hermus AR; Lenders JW; Deinum J
J Clin Endocrinol Metab; 2016 Jul; 101(7):2826-35. PubMed ID: 27172433
[TBL] [Abstract][Full Text] [Related]
38. Relationship Between 18F-FDG PET/CT Findings and HER2 Expression in Gastric Cancer.
Chen R; Zhou X; Liu J; Huang G
J Nucl Med; 2016 Jul; 57(7):1040-4. PubMed ID: 26966162
[TBL] [Abstract][Full Text] [Related]
39. The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline.
Funder JW; Carey RM; Mantero F; Murad MH; Reincke M; Shibata H; Stowasser M; Young WF
J Clin Endocrinol Metab; 2016 May; 101(5):1889-916. PubMed ID: 26934393
[TBL] [Abstract][Full Text] [Related]
40. Pharmacological treatment of aldosterone excess.
Deinum J; Riksen NP; Lenders JW
Pharmacol Ther; 2015 Oct; 154():120-33. PubMed ID: 26213109
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
